PMID- 36193071
OWN - NLM
STAT- MEDLINE
DCOM- 20221005
LR  - 20221006
IS  - 1942-0994 (Electronic)
IS  - 1942-0900 (Print)
IS  - 1942-0994 (Linking)
VI  - 2022
DP  - 2022
TI  - Mitochondria-Targeted Antioxidant Mitoquinone Maintains Mitochondrial Homeostasis 
      through the Sirt3-Dependent Pathway to Mitigate Oxidative Damage Caused by Renal 
      Ischemia/Reperfusion.
PG  - 2213503
LID - 10.1155/2022/2213503 [doi]
LID - 2213503
AB  - Mitochondrial dysfunction is a critical factor contributing to oxidative stress 
      and apoptosis in ischemia-reperfusion (I/R) diseases. Mitoquinone (MitoQ) is a 
      mitochondria-targeted antioxidant whose potent anti-I/R injury capacity has been 
      demonstrated in organs such as the heart and the intestine. In the present study, 
      we explored the role of MitoQ in maintaining mitochondrial homeostasis and 
      attenuating oxidative damage in renal I/R injury. We discovered that the 
      decreased renal function and pathological damage caused by renal I/R injury were 
      significantly ameliorated by MitoQ. MitoQ markedly reversed mitochondrial damage 
      after I/R injury and inhibited renal reactive oxygen species production. In 
      vitro, hypoxia/reoxygenation resulted in increased mitochondrial fission and 
      decreased mitochondrial fusion in human renal tubular epithelial cells (HK-2), 
      which were partially prevented by MitoQ. MitoQ treatment inhibited oxidative 
      stress and reduced apoptosis in HK-2 cells by restoring mitochondrial membrane 
      potential, promoting ATP production, and facilitating mitochondrial fusion. 
      Deeply, renal I/R injury led to a decreased expression of sirtuin-3 (Sirt3), 
      which was recovered by MitoQ. Moreover, the inhibition of Sirt3 partially 
      eliminated the protective effect of MitoQ on mitochondria and increased oxidative 
      damage. Overall, our data demonstrate a mitochondrial protective effect of MitoQ, 
      which raises the possibility of MitoQ as a novel therapy for renal I/R.
CI  - Copyright (c) 2022 Hu Mao et al.
FAU - Mao, Hu
AU  - Mao H
AUID- ORCID: 0000-0003-2252-5572
AD  - Department of Urology, Renmin Hospital of Wuhan University, Wuhan, 430060 Hubei, 
      China.
FAU - Zhang, Ye
AU  - Zhang Y
AUID- ORCID: 0000-0001-9945-6777
AD  - Department of Urology, Renmin Hospital of Wuhan University, Wuhan, 430060 Hubei, 
      China.
FAU - Xiong, Yufeng
AU  - Xiong Y
AUID- ORCID: 0000-0001-9810-1691
AD  - Department of Urology, Renmin Hospital of Wuhan University, Wuhan, 430060 Hubei, 
      China.
FAU - Zhu, Zijing
AU  - Zhu Z
AUID- ORCID: 0000-0003-2615-3040
AD  - Division of Nephrology, Renmin Hospital of Wuhan University, Wuhan, 430060 Hubei, 
      China.
FAU - Wang, Lei
AU  - Wang L
AUID- ORCID: 0000-0001-8412-1130
AD  - Department of Urology, Renmin Hospital of Wuhan University, Wuhan, 430060 Hubei, 
      China.
FAU - Liu, Xiuheng
AU  - Liu X
AUID- ORCID: 0000-0003-3882-2715
AD  - Department of Urology, Renmin Hospital of Wuhan University, Wuhan, 430060 Hubei, 
      China.
LA  - eng
PT  - Journal Article
DEP - 20220920
PL  - United States
TA  - Oxid Med Cell Longev
JT  - Oxidative medicine and cellular longevity
JID - 101479826
RN  - 0 (Antioxidants)
RN  - 0 (Organophosphorus Compounds)
RN  - 0 (Reactive Oxygen Species)
RN  - 1339-63-5 (Ubiquinone)
RN  - 47BYS17IY0 (mitoquinone)
RN  - 8L70Q75FXE (Adenosine Triphosphate)
RN  - EC 3.5.1.- (SIRT3 protein, human)
RN  - EC 3.5.1.- (Sirtuin 3)
SB  - IM
MH  - Adenosine Triphosphate/metabolism
MH  - Antioxidants/metabolism/pharmacology
MH  - Homeostasis
MH  - Humans
MH  - Ischemia/metabolism
MH  - *Kidney Diseases/metabolism
MH  - Mitochondria/metabolism
MH  - Organophosphorus Compounds/metabolism/pharmacology
MH  - Oxidative Stress
MH  - Reactive Oxygen Species/metabolism
MH  - Reperfusion/adverse effects
MH  - *Reperfusion Injury/pathology
MH  - *Sirtuin 3/metabolism
MH  - Ubiquinone/analogs & derivatives/metabolism/pharmacology
PMC - PMC9526615
COIS- The authors declare no conflict of interest.
EDAT- 2022/10/05 06:00
MHDA- 2022/10/06 06:00
PMCR- 2022/09/20
CRDT- 2022/10/04 01:54
PHST- 2022/06/24 00:00 [received]
PHST- 2022/08/29 00:00 [revised]
PHST- 2022/09/01 00:00 [accepted]
PHST- 2022/10/04 01:54 [entrez]
PHST- 2022/10/05 06:00 [pubmed]
PHST- 2022/10/06 06:00 [medline]
PHST- 2022/09/20 00:00 [pmc-release]
AID - 10.1155/2022/2213503 [doi]
PST - epublish
SO  - Oxid Med Cell Longev. 2022 Sep 20;2022:2213503. doi: 10.1155/2022/2213503. 
      eCollection 2022.